Switch theme
Sign up to access all valuation multiples
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
1992
9.8K+
LTM Revenue $2.2B
LTM EBITDA $370M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Joincare Pharmaceutical has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $370M.
In the most recent fiscal year, Joincare Pharmaceutical achieved revenue of $2.2B and an EBITDA of $630M.
Joincare Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Joincare Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $370M | XXX | $630M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $512M | XXX | $492M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $197M | XXX | $194M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Joincare Pharmaceutical's stock price is CNY 11 (or $2).
Joincare Pharmaceutical has current market cap of CNY 20.4B (or $2.9B), and EV of CNY 10.8B (or $1.5B).
See Joincare Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $2.9B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Joincare Pharmaceutical has market cap of $2.9B and EV of $1.5B.
Joincare Pharmaceutical's trades at 0.7x EV/Revenue multiple, and 2.4x EV/EBITDA.
Equity research analysts estimate Joincare Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Joincare Pharmaceutical has a P/E ratio of 14.5x.
See valuation multiples for Joincare Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 4.1x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBIT | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.5x | XXX | 14.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJoincare Pharmaceutical's last 12 month revenue growth is 5%
Joincare Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Joincare Pharmaceutical's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Joincare Pharmaceutical's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Joincare Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | -23% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Joincare Pharmaceutical acquired XXX companies to date.
Last acquisition by Joincare Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Joincare Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Joincare Pharmaceutical founded? | Joincare Pharmaceutical was founded in 1992. |
| Where is Joincare Pharmaceutical headquartered? | Joincare Pharmaceutical is headquartered in China. |
| How many employees does Joincare Pharmaceutical have? | As of today, Joincare Pharmaceutical has 9.8K+ employees. |
| Is Joincare Pharmaceutical publicy listed? | Yes, Joincare Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Joincare Pharmaceutical? | Joincare Pharmaceutical trades under 600380 ticker. |
| When did Joincare Pharmaceutical go public? | Joincare Pharmaceutical went public in 2001. |
| Who are competitors of Joincare Pharmaceutical? | Similar companies to Joincare Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Joincare Pharmaceutical? | Joincare Pharmaceutical's current market cap is $2.9B |
| What is the current revenue of Joincare Pharmaceutical? | Joincare Pharmaceutical's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Joincare Pharmaceutical? | Joincare Pharmaceutical revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Joincare Pharmaceutical? | Current revenue multiple of Joincare Pharmaceutical is 0.7x. |
| Is Joincare Pharmaceutical profitable? | Yes, Joincare Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Joincare Pharmaceutical? | Joincare Pharmaceutical's last 12 months EBITDA is $370M. |
| What is Joincare Pharmaceutical's EBITDA margin? | Joincare Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Joincare Pharmaceutical? | Current EBITDA multiple of Joincare Pharmaceutical is 4.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
